| 2017 | A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017)
| 김주항, 김혜련, 정인경, 조병철 |
| 2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | 김주항, 김혜련, 심효섭, 임선민, 조병철 |
| 2016 | Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma | 고윤우, 김주항, 김혜련, 이창걸, 조병철, 최은창 |
| 2016 | Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer
| 금기창, 김세헌, 김주항, 김준원, 이창걸 |
| 2016 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
| 김민환, 김주항, 김혜련, 문용화, 백순명, 임선민, 조병철 |
| 2016 | Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
| 김영진, 김주항, 문용화, 서영주, 심효섭, 이혜정, 임동진, 조응혁, 최병욱, 허진, 홍유진 |
| 2016 | Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells | 김주항, 송재진, 최혜진 |
| 2016 | Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy | 김주항, 김혜련, 박형순, 이민구, 조병철, 조응혁 |
| 2015 | An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer | 강상욱, 강찬우, 김주항, 김혜련, 남기현, 임선민, 임재윤, 정웅윤, 조병철 |
| 2015 | LAMC2 enhances the metastatic potential of lung adenocarcinoma | 김주항, 문용화, 심효섭, 정현철 |
| 2015 | Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells | 김주항, 송재진, 최혜진 |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | 고윤우, 권형주, 김주항, 김한상, 김혜련, 백순명, 이민구, 이지현, 정인경, 조병철, 최은창 |
| 2015 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
| 김대준, 김주항, 김현기, 김혜련, 김효송, 박준철, 신성관, 이상길, 이용찬, 이창걸, 정다현, 조병철, 허진 |
| 2015 | The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer | 김대준, 김세규, 김은영, 김주항, 김혜련, 김효송, 심효섭, 이창영, 장준, 정인경, 정지예, 조병철 |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| 김대준, 김주항, 김현기, 김혜련, 김효송, 문용화, 박준철, 백순명, 신성관, 이상길, 이용찬, 이창걸, 정현수, 조병철, 표경호, 허진 |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| 강찬우, 강한나, 김대준, 김주항, 김혜련, 김환, 문용화, 백순명, 윤미란, 임선민, 장강원, 조병철, 표경호 |
| 2015 | Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest | 김주항, 송재진 |
| 2015 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication
| 구자승, 김민환, 김승일, 김주항, 박병우, 박세호, 박형석, 손주혁, 정준 |
| 2014 | Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
| 김대준, 김세규, 김은영, 김주항, 김한상, 김혜련, 배미경, 심효섭, 이민구, 이지현, 이진구, 이창영, 장준, 정경영, 정지예, 조병철 |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | 강대용, 김민환, 김은영, 김주항, 김혜련, 배미경, 이재석, 이창영, 조병철 |
| 2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | 김대준, 김세규, 김주항, 김혜련, 심효섭, 임선민, 장준, 조병철 |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | 김대준, 김민환, 김은영, 김주항, 김현정, 김혜련, 배미경, 심효섭, 이진구, 이창영, 임선민, 정경영, 정지예, 조병철 |
| 2014 | Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors | 김주항, 박희진, 조병철 |
| 2014 | Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus | 김주항, 송재진 |
| 2014 | Clinical Outcome According to the Level of Preexisting Epidermal Growth Factor Receptor T790M Mutation in Patients With Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations | 김주항 |
| 2014 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | 김주항 |
| 2014 | A prospective phase II trial of s-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer | 김대준, 김주항, 김충배, 김형일, 김혜련, 박준철, 배미경, 신성관, 이상길, 이용찬, 이진구, 이창걸, 이창영, 이혁, 조병철, 차지혜, 허진 |
| 2013 | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | 김건민, 김다래, 김세규, 김세현, 김영삼, 김은영, 김주항, 김한상, 김혜련, 박무석, 박지수, 이준호, 임선민, 임승택, 장준, 정지예, 조병철 |
| 2013 | Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation | 김선미, 김주항, 조병철 |
| 2013 | Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
| 강영애, 김대준, 김세규, 김주항, 라선영, 박형순, 이지현, 이철호, 장준, 정민규, 조병철 |
| 2013 | Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer
| 강창무, 김주항, 송시영, 윤미진, 이우정, 이재훈, 이종두, 조응혁, 최혜진 |
| 2013 | Better Outcome of XELOX Chemotherapy in Patients with Advanced Intestinal-Type Adenocarcinoma of the Ampulla of Vater
| 김주항, 김한상, 김현기, 신상준, 최혜진 |
| 2013 | A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes | 강상욱, 김주항, 김현정, 남기현, 박정수, 윤미진, 임선민, 정웅윤, 조병철 |
| 2013 | A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) | 김선미, 김세현, 김주항, 김혜련, 심효섭, 장현, 조병철, 조재호, 홍윤경 |
| 2013 | TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex | 김주항, 송재진 |
| 2013 | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
| 김주항, 김혜련, 배미경, 심효섭, 조병철 |
| 2013 | Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment: Inhibition of apoptosis by caspase degradation. | 김주항, 송재진 |
| 2013 | Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA | 김주항, 송재진 |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | 김승일, 김주항, 박병우, 박세호, 손주혁, 이수현, 임승택, 최혜진, 한정우 |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| 구자승, 김민정, 김승일, 김은경, 김주항, 박병우, 박세호, 손주혁, 이수현, 정현철 |
| 2013 | c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5 | 김주항, 송재진 |
| 2013 | The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
| 김주항, 김혜련, 남기창, 라선영, 안정련, 이진구, 조병철, 홍윤경 |
| 2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | 강대용, 김대준, 김세훈, 김주항, 김혜련, 라선영, 배미경, 심효섭, 이지현, 이진구, 이창영, 임선민, 정경영, 조병철 |
| 2013 | The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy | 김주항, 송재진 |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| 김주항, 김한상, 김효송, 노재경, 라선영, 손주혁, 신상준, 안중배, 이수현, 정현철, 조병철, 최혜진 |
| 2012 | High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
| 김세훈, 김주항, 박무석, 심효섭, 조병철 |
| 2012 | Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients | 강영애, 김건민, 김선미, 김세규, 김영삼, 김주항, 임승택, 조병철 |
| 2012 | Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation | 권오준, 김선미, 김주항, 이지현, 조병철, 홍윤경 |
| 2012 | Treatment outcome of patients with anaplastic thyroid cancer: a single center experience
| 강상욱, 금기창, 김주항, 남기현, 박정수, 신상준, 임선민, 정웅윤, 조병철, 조재용 |
| 2012 | Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer | 김세현, 김주항, 김혜련, 윤상현, 이창걸, 장현, 조병철 |
(Yonsei Health Research Network)
